Table 1. Associations between oncological treatments and manifestations of cardiotoxicity (according to 5, 39, 40, e1–e8, e20, e21).
| Drug | Restricted left ventricular function % |
Cardiac ischemia % |
Association with arterial hypertension % |
Association with thromboembolism % |
|---|---|---|---|---|
| Anthracyclines Doxorubicin Epirubicin Idarubicin Liposomal anthracyclines |
3 to 26 0.9 to 3.3 5 to 18 2 |
– – – – |
– – – – |
– – – – |
| Alkylating agents Cyclophosphamide Ifosfamide Cisplatin |
7 to 28 17 – |
– – - |
– – - |
– – 8.5 |
| Antimetabolites Clofarabine Capecitabine 5-Fluoruracil |
27 – – |
– 3 to 9 1 to 68 |
– – - |
– – – |
| Antimicrotubule agents Docetaxel Paclitaxel |
2.3 to 8 – |
1.7 1 to 5 |
– – |
– – |
| Monoclonal antibodies Bevacizumab Trastuzumab |
1.7 to 3 2 to 28 |
0.6 to 1.5 – |
4 to 35 – |
12 – |
| Proteasome inhibitors Bortezomib |
2 to 5 |
– |
– |
– |
| Small-molecule tyrosine kinase inhibitors Dasatinib Imatinib Lapatinib Sunitinib Erlotinib Sorafenib |
2 to 4 0.5 to 1.7 1.5 to 2.2 2.7 to 11 – – |
– – – – 2.3 2.7 to 3 |
– – – 5 to 47 – 17 to 43 |
– – – – 3.9 to 11 – |
| Immunomodulators/piperidinediones Lenalidomide Thalidomide |
– – |
– – |
– – |
3 to 75 1 to 58 |
| Radiotherapy | >4 | 1 to 13 | – | – |